Please login to the form below

Not currently logged in
Email:
Password:

Accelerated approval not working

The US FDA's accelerated approval programme for NMEs is not achieving its aim, according to a multi-centre study

The US Food and Drug Administration's (FDA's) accelerated approval programme for new molecular entities (NMEs) is not achieving its aim, according to a multi-centre study published in the Journal of Clinical Oncology.

The initiative was set up in 1992 to try to speed up access to therapies for life-threatening conditions, including cancer. Researchers looked at data for accelerated and regular FDA approvals in oncology since 1995. The study shows that oncology NMEs in the accelerated programme reached market in a median time of 7.3 years and new drugs going through regular approval took a median of 7.2 years.

One of the problems, particularly for small biotech companies, is the cost of the large-scale studies now required by the regulators. The authors call for the FDA to return to basing approval for potentially life-saving drugs on smaller studies, in order to expedite access to new treatments for patients with terminal conditions.

28th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics